4. The pharmaceutical composition according to claim 2, wherein the polyoxyethylene hardened castor oil includes polyoxyethylene hardened castor oil selected from the group consisting of polyoxyethylene hardened castor oil 10, polyoxyethylene hardened castor oil 40, polyoxyethylene hardened castor oil 50, and polyoxyethylene hardened castor oil 60.

5. The pharmaceutical composition according to claim 2, wherein the polyoxyethylene sorbitan fatty acid ester includes polyoxyethylene sorbitan fatty acid ester selected from the group consisting of Polysorbate 80, Polysorbate 60, Polysorbate 40, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan trioleate, and Polysorbate 65.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the content of the nonionic surfactant is in a range of 0.001 to 5% (w/v).

7. The pharmaceutical composition according to claim 6, wherein the content of the nonionic surfactant is in a range of 0.8 to 2% (w/v).

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the content of the nonionic surfactant is in a range of 1 to 20,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-

ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.0001 to 0.1% (w/v).

10. The pharmaceutical composition according to claim 9, wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.001 to 0.003% (w/v).

11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the content of edetic acid or a salt thereof is in a range of 0.001 to 1% (w/v).

12. The pharmaceutical composition according to claim 11, wherein the content of edetic acid or a salt thereof is in a range of 0.01 to 0.1% (w/v).

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the content of edetic acid or a salt thereof is in a range of 3 to 1,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-